Thermo Fisher Scientific this week announced that President and CEO Marijn Dekkers has resigned to become the CEO of German life science, drug, and chemical firm Bayer. Marc Casper, currently Thermo Fisher's executive vice president and chief operating officer, will succeed Dekkers in both positions, effective Oct. 15.
Casper also will replace Dekkers as a board member.
Dekkers leave Thermo Fisher having directed it to become one of the largest life-science companies in the world as well as the second-largest mass spectrometer vendor after Life Technologies' Applied Biosystems, whose mass spec joint venture is being acquired by Danaher.
Born in Holland, Dekkers, 51, started his career in the life sciences in 1985 as a researcher for General Electric in Schenectady, New York. Eventually, he held a number of management positions at GE before moving to AlliedSignal, now called Honeywell International, in 1995.
In 2000, he landed at Thermo Fisher as COO when it was still called Thermo Electron. Two years later, he became its CEO and president. Since joining Thermo Fisher, the company has grown from a business with sales of $2.2 billion and a workforce of 11,000 to one with sales of $10.5 billion and 35,000 employees.
In 2006, Thermo Electron merged with Fisher Scientific in a $10.6 billion transaction that fused a leading instruments and equipment manufacturer, Thermo, with a leading chemistry and consumables firm, Fisher.
During Dekker's tenure, Thermo Fisher has solidified its position as a technology leader in mass specs. Its Orbitrap technology, first commercialized in 2005, is viewed as a transformative technology, especially in the study of post-translational modifications. The latest iteration of the technology, the LTQ Orbitrap Velos, was unveiled at the American Society for Mass Spectrometry annual conference this spring.
Thermo Fisher further strengthened its position in proteomics during his time by creating the Biomarker Research Initiatives in Mass Spectrometry, or BRIMS, center in 2004, which has collaborated on research with partners such as the University Health Network in Toronto and George Mason University.
Last year, the company also in-licensed the Tandem Mass Tag isobaric mass-labeling technology from Proteome Sciences last year.
Dekkers will become CEO of Bayer effective Oct. 1, 2010. He replaces Werner Wenning who has served as Bayer's CEO since 2002.
Dekkers will join the Bayer Management Board on Jan. 1, 2010 and serve as CEO of Bayer Healthcare during a transition phase. He replaces Arthur Higgins who has been CEO of that division since Jan. 1, 2006. Higgins is leaving for personal reasons, Bayer said in a statement.
Prior to his becoming EVP and COO, Casper had been president of Thermo Electron's analytical technologies business. He joined the company in December 2001 as president of its Life and Laboratory Sciences sector. Before that, he was president, CEO, and a director at Kendro Laboratory Products. Before that he was president of Dade Behring's American operations.
MDS announced this week its CEO and president, Stephen DeFalco, will be stepping down from those posts to be replaced by Steve West.
West, currently president of MDS Nordion, was also appointed Chief Operating Officer, and will replace DeFalco when MDS completes its transition to focus solely on the Nordion business.
On Sept. 2, MDS announced the sale of its MDS Analytical Technologies division to Danaher and, separately, its intention to sell the MDS Pharma Services Business. Assuming completion of both deals, MDS would consist solely of the Nordion business.
West became president of MDS Nordion in 2003, after starting his career at MDS as a senior partner at MDS Capital. Prior to that, he was president of DiverseyLever Canada. He has held a variety of CEO positions in Asia and the Pacific Rim as well as international business development responsibilities in the specialty chemicals field, the company said in a statement. He holds a degree in genetics from the University of London and completed his post-graduate research in biotechnology.
DeFalco became president and CEO of MDS on July 1, 2005 after joining the firm less than a month earlier as COO. Prior to MDS, he was chairman and CEO of US Genomics. Before that, he served as president of PerkinElmer Instruments and senior vice president of PerkinElmer.
Caris Diagnostics this week announced the appointment of Thomas Spalding as senior vice president and Chief Marketing Officer.
Spalding will be responsible for all corporate marketing, portfolio management, consumer marketing, and strategic branding.
Spalding spent 18 years at Johnson & Johnson where he was most recently worldwide vice president of marketing for J&J's oncology diagnostics firm Veridex. He was responsible for strategy and marketing of the CellSearch and GeneSearch cancer diagnostic products.
Based in Irving, Texas, Caris develops diagnostics and anatomic pathology services in oncology, dermatopathology, hematopathology, and gastrointestinal pathology.
Pressure Biosciences said today that Thomas Vogel has resigned from its board. Alan Rosenson was elected to replace him.
Vogel had been a director at PBI since January 2004. He will continue to be a consultant to the company on an as-needed basis until Sept. 15, 2011, PBI said in a statement.
Rosenson is currently the president of Aljar investments, which he founded in 1994. In 1987, he founded Consulting Innovations, an informations firm, which currently provides consulting services and technology training to high-level executives and business owners.
He received his MBA from Washington University and his BA from Indiana University.